MEA Psychiatry Therapies Market

MEA Psychiatry Therapies Market Size (2023 to 2028)

The size of the psychiatry therapies market in the Middle East and Africa is estimated to grow at a sluggish rate from 2023 to 2028.

As a result of increased stress levels emotional, physical, and mental pressure among the population, the demand for psychiatric therapies is increasing, resulting in the growth of the MEA psychiatry therapies market. In addition, psychiatric facilities are implementing mobile and connected technologies to aid in diagnosing and treating mental illness. Electronic medical records, for example, are quickly becoming commonplace as a way to document, communicate, and support clinical decision-making. These technologies provide real-time visibility into patient health through active and passive data collecting.

Patients' conditions, such as behavioral patterns and physiological sensations, can also be monitored using new e-tools. It helps mental care professionals to develop new psychiatric diagnostic tests. As the number of people with psychological disorders rises, the demand for treatment will result in market expansion. In addition, the market for psychiatry therapies would be fueled by the rise in chronic diseases and anxiety disorders. Economic growth and rising disposable incomes in emerging economies, government initiatives for mental health reforms, and technical advancements in healthcare all contributed to development over the historic period.  Growth will be driven in the future by increased economic growth, private health insurance changes, and increased social acceptance of mental health disorders.

Middle East Africa faces formidable challenges in dealing with a rising burden of mental illness, frequently in harsh conditions that will have long-term consequences. Limited healthcare access in this low-income country and societal stigma associated with mental illness were factors that hampered growth during the historic period. However, the market is hindered by strict government rules for practicing psychotherapy. Shortages of mental health experts and high psychiatric service costs are two factors that could slow the growth of the psychiatrists’ market in the future. On the other hand, the absence of healthcare IT professionals and the low rate of adoption of mental health electronic health records (EHRs) are projected to limit the market's growth. While the prevalence of mental-health diseases in most MEA nations is higher than the worldwide average, the human resources, policies, money, and infrastructure needed to address these issues are severely deficient.

This research report on the MEA psychiatry therapies market has been segmented and sub-segmented into the following categories:

• By Psychology Type: Social Psychology, Abnormal Psychology, Biological Psychology, and Others
• By Type of Medication: Antidepressants, Antipsychotics, Depressants, Anxiolytics, Mood Stabilisers, Stimulants, and Others
• By Type of Therapy: Counselling, Cognitive Behavioural Therapy, Family Therapy, Psychotherapy, Group Therapy, Relationship Counselling, Interpersonal Therapy, Behavioural Activation, and Others
• By Country: KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA

Although additional signs of neglect have arisen since then, Egypt passed a law in 2009 to speed up the supply of mental healthcare, protect patients' rights, and give them more say in treatment. Following that, Iraq revamped its mental-health system to accommodate more outstanding care outside of hospitals. Kuwait, Lebanon, and even Syria have tried to decentralize therapy and integrate mental health care into basic care. Jordan was able to create three local mental-health centers due to donor financing in 2008-9, leading to more complete changes. The Arabian culture in Middle East Africa has always dismissed mental health as a legitimate social issue. Still, with advances in technology and an openness to new ideas and ideologies, there is now a push to break down the barriers to mental health awareness in these countries and cultures.

KEY MARKET PLAYERS:

Companies operating in the MEA Psychiatry Therapies market are AstraZeneca, Universal Health Services Inc., Johnson & Johnson, Pfizer, GlaxoSmithKline, Eli Lilly, Bristol-Meyer Squibb, Wyeth, Astellas Pharma Inc., and others.